Company: NCEL
Filing Date: 2025-01-07
Form Type: 6-K
Source: 0001213900-25-001667
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-01-07
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2025

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

Extraordinary Shareholders’ Meeting Results

On January 7, 2025, NLS Pharmaceutics
Ltd., or the Registrant, convened an extraordinary shareholders’ meeting, or the Meeting. At the Meeting, a quorum was present,
and the shareholders of the Registrant approved all agenda items, except for Proposal 6, as originally proposed. Proposal 6 was not approved
because it was not put to a vote at the Meeting.

The Report on Form 6-K is
incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-282788, 333-262489, 333-268690
and 333-269220), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: January 7, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:----------------------|:-----------------------|:--------------------|:------------------------|
|                       |                        | Name:               | Alexander Zwyer         |
|                       |                        | Title:              | Chief Executive Officer |

<div align='center'>2</div>